title: A review of the effects of the oral direct thrombin inhibitor ximelagatran on coagulation assays.
authors.affiliation: AstraZeneca R&D Mölndal, Mölndal, Sweden. Stefan.c.carlsson@astrazeneca.com
authors.forename: Stefan C
authors.initials: SC
authors.lastname: Carlsson
authors.forename: Christer
authors.initials: C
authors.lastname: Mattsson
authors.forename: Ulf G
authors.initials: UG
authors.lastname: Eriksson
authors.forename: Troy C
authors.initials: TC
authors.lastname: Sarich
authors.forename: Karin
authors.initials: K
authors.lastname: Wåhlander
authors.forename: Asa
authors.initials: A
authors.lastname: Eliasson
authors.forename: Björn W
authors.initials: BW
authors.lastname: Karlson
authors.forename: Sunita B
authors.initials: SB
authors.lastname: Sheth
authors.forename: Peter
authors.initials: P
authors.lastname: Held
mesh_terms: D001384:Azetidines / Q000494:pharmacology*; D001596:Benzylamines; D001777:Blood Coagulation / Q000187:drug effects*; D001780:Blood Coagulation Tests; D004305:Dose-Response Relationship, Drug; D006801:Humans; D020128:Inhibitory Concentration 50
chemical_list: D001384:Azetidines; D001596:Benzylamines; C426686:ximelagatran